U.S. Drug Prices Should Reflect Value to Patients: Expert Panel

A panel of medical experts said on Friday the prices of prescription medicines in the United States need to be brought in line with the value they bring to patients instead of continuing to let drugmakers set any price they choose.

“Americans at the same time are getting tremendously ripped off with drugs and also getting tremendous value and we almost never know when we’re getting ripped off and when we’re getting real value and that has to change,” said Steven Pearson, president of the Institute for Clinical and Economic Review (ICER), an independent non-profit group that evaluates clinical and cost effectiveness of new medicines.

Panelists taking part in Drug Pricing: Public Health Implications, presented by Harvard T.H. Chan School of Public Health in collaboration with Reuters, saw serious limitations in solutions being proposed by politicians to rein in prices that are vastly higher than what the rest of the world pays.

Democratic presidential candidate Hillary Clinton recently proposed capping patient co-pays as a way to help people cope with rising out-of-pocket medical costs.

But Meredith Rosenthal, professor of Health Economics and Policy at Harvard, likened that to minor pain relief. “The patient is bleeding and now you’ve numbed it … and you haven’t gotten to the root of the problem.”

Calls to allow the government Medicare program to negotiate drug prices as it does the cost of so many other aspects of medical care were deemed unrealistic or problematic.

“In this country we are millions of miles away from the idea that Medicare is going to have some kind of stamp to say here is the price of a drug,” ICER’s Pearson said.

New cancer treatments that can cost well over $100,000 a year, and far more when combination therapies are used, were of particular concern.

“I’m appalled at how many Americans are going into bankruptcy because of outrageous costs,” said Dr. Lowell Schnipper, chairman of the American Society of Clinical Oncology’s Value in Cancer Care Task Force.

He called for a systematic way to determine if a new cancer medicine is of low, medium or high value to patients, and suggested perhaps only paying for drugs when they work.

Schnipper was not in favor of solutions that remove incentives for drugmakers to spend money needed to develop important new medicines.

“As a doctor who treats patients I want new drugs,” he said. “Some of these are nothing short of miraculous. We need to reward innovation in some way.”

Source Link

Recommended Articles

White House Leaves One Trump-Era Policy Alone

The Biden administration has gutted many of former President Donald Trump’s health care policies, but there’s one that the White House has yet to touch, Kelly reports. It’s a 2019 rule that expanded individual coverage health reimbursement arrangements, or ICHRAs, which allowed employers to provide tax-exempt subsidies to help workers purchase Obamacare plans. The Biden administration’s ...

Read More

Court Strikes Down HHS Rule that Allowed Insurers to Not Count Copay Assistance

In a major victory for patients who depend on prescription drugs, Judge John D. Bates of the U.S. District Court for the District of Columbia struck down a Trump administration federal rule that allowed health insurers to not count drug manufacturer copay assistance towards a beneficiary’s out-of-pocket costs. The case was brought against the U.S. Department of Health and ...

Read More

Lawmakers, Payers And Providers All Air Grievances With Federal No Surprises Act Implementation

Amid a flurry of partisan roadblocks rolling out across Capitol Hill, representatives on both sides of the aisle came together Tuesday to critique federal agencies’ rollout of the No Surprises Act and throw their support behind court-ordered rewrites of independent dispute resolution (IDR) regulations. During a hearing exploring the “flawed implementation” of the law intended ...

Read More

As Biden Plans To Ban Medical Debt From Credit Scores, Advocates Press For More Change

The dramatic impact of medical debt on credit scores may soon be a thing of the past. On Thursday, the White House announced a plan outlined by the Consumer Financial Protection Bureau (CFPB) to eliminate medical debt from credit reports. The move — which follows an earlier decision from the three main credit bureaus to eliminate paid medical debt, medical ...

Read More